Christopher Raymond Analyst PerformanceManaging Director at Piper SandlerChristopher Raymond is a stock analyst at Piper Sandler in the medical sector, covering 23 publicly traded companies. Over the past year, Christopher Raymond has issued 12 stock ratings, including strong buy, buy, and hold recommendations. While full access to Christopher Raymond's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Christopher Raymond's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings57 Last 11 YearsBuy Recommendations74.55% 41 Buy RatingsCompanies Covered23 Unique Companies Ratings Distribution55RatingsDistribution of strong buy, buy, hold, and sell ratings by Christopher Raymond.RatingPercentageCount Strong Buy14.5%8 ratings Buy60.0%33 ratings Hold25.5%13 ratings Sell0.0%0 ratingsOut of 55 total stock ratings issued by Christopher Raymond at Piper Sandler, the majority (60.0%) have been Buy recommendations, followed by 25.5% Hold and 14.5% Strong Buy.Best & Worst CallsBest Call0000.0%RAREDec 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ALXONov 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ91.3% of companies on NASDAQ21 companiesNYSE8.7% of companies on NYSE2 companiesChristopher Raymond, an analyst at Piper Sandler, currently covers 23 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical23 companies100.0%Christopher Raymond of Piper Sandler specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE17 companies73.9%MED - DRUGS2 companies8.7%PHARMACEUTICAL PREPARATIONS2 companies8.7%MED - GENERIC DRG1 company4.3%LARGE CAP PHARMA1 company4.3% Christopher Raymond's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCLYMClimb Bio3/10/2026Initiated Coverage$7.33$25.00Strong-Buy$0.0000.00% ROIALMSAlumis3/10/2026Initiated Coverage$28.10$46.00Strong-Buy$0.0000.00% ROICOGTCogent Biosciences2/18/2026Boost Price Target$37.62$52.00Overweight$0.0000.00% ROIARDXArdelyx1/8/2026Upgrade$7.00$16.00Overweight$0.0000.00% ROITSHATaysha Gene Therapies1/6/2026Reiterated Rating$5.24$13.00Strong-Buy$0.0000.00% ROILXEOLexeo Therapeutics12/17/2025Initiated Coverage$9.11$25.00Strong-Buy$0.0000.00% ROILXEOLexeo Therapeutics12/17/2025Upgrade$10.35Strong-Buy$0.0000.00% ROIARDXArdelyx11/4/2025Boost Price Target$5.88$10.00Neutral$0.0000.00% ROITSHATaysha Gene Therapies10/21/2025Initiated Coverage$4.72$13.00Strong-Buy$0.0000.00% ROIMGTXMeiraGTx10/21/2025Initiated Coverage$8.24$29.00Strong-Buy$0.0000.00% ROIARDXArdelyx8/6/2025Boost Price Target$5.09$9.00Neutral$0.0000.00% ROIABVXAbivax7/23/2025Boost Price Target$67.67$70.00Overweight$0.0000.00% ROIITOSiTeos Therapeutics5/14/2025Set Price Target$7.52$12.00$0.0000.00% ROIBIIBBiogen4/29/2025Lower Price Target$120.39$115.00Neutral$000.0000.00% ROIALXOALX Oncology3/6/2025Boost Price Target$1.24$9.00Overweight$0.0000.00% ROIBMRNBioMarin Pharmaceutical2/20/2025Boost Price Target$65.61$126.00Overweight$00.0000.00% ROIBIIBBiogen2/18/2025Reiterated Rating$138.59$135.00Neutral$000.0000.00% ROIQTTBQ32 Bio2/11/2025Downgrade$3.18$4.00Neutral$0.0000.00% ROIARDXArdelyx1/27/2025Boost Price Target$5.69$8.00Neutral$0.0000.00% ROIBPMCBlueprint Medicines1/27/2025Boost Price Target$116.60$119.00Neutral$0.0000.00% ROIVRTXVertex Pharmaceuticals1/27/2025Lower Price Target$441.51$533.00Overweight$000.0000.00% ROIREGNRegeneron Pharmaceuticals1/27/2025Lower Price Target$688.17$1,013.00Overweight$000.0000.00% ROIRAREUltragenyx Pharmaceutical1/13/2025Boost Price Target$41.54$140.00Overweight$00.0000.00% ROIINZYInozyme Pharma1/13/2025Lower Price Target$1.75$30.00Overweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
